Rezlidhia (Olutasidenib) Patent Expiration, LOE Window & CMS Spending

Rezlidhia (Olutasidenib) by Rigel Pharmaceuticals: FDA Orange Book core substance LOE 2039-05-16 (last listed 2039-11-12), 0 AB generics, $15.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRigel Pharmaceuticals
FDA Application & PathwayN215814 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-05-16
Last Listed Patent or Exclusivity Date2039-11-12
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$15.9M
2024 Medicare Part D Spend$15.5M
2024 Medicaid Spend$462K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel